Examined marker HER-2 is a critical and therapeutic target, especially in breast, gastric, and lung cancer, mainly assessed via IHC and fluorescence in situ hybridization to determine the degree of tumor aggressiveness. The gene discussed is ERBB2; the disease is lung carcinoma.